Skip to content

Activator and Type II Diabetics

Effect of Activator Methods Technique on Lowering A1c Levels in Type II Diabetics

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01782092
Enrollment
5
Registered
2013-02-01
Start date
2012-08-31
Completion date
2014-08-31
Last updated
2016-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type II Diabetes

Keywords

diabetes

Brief summary

The purpose of this study (15-subject prospective case series) is to examine the effects of the Activator Methods technique on decreasing A1c levels in patients with type II Diabetes Mellitus (aka adult-onset diabetes).

Interventions

Chiropractic adjustments will be administered using Activator Methods Basic protocol

Sponsors

Life University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
30 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Subjects will be eligible to participate in the study if they are between the ages of 30-60 and are clinically diagnosed with Type II diabetes by their primary care providers or endocrinologists (diagnosis usually based on FPG \> 126 mg/dL on two occasions). * Participants must have been diagnosed for at least one year and currently be under medical supervision for the disease. * They must also have an A1c measurement above 7%, which indicates less than optimal management of the disease.

Exclusion criteria

* The study will exclude pregnant women; * those with co-morbidities affecting life expectancy (e.g. malignancy, CVD); uncontrolled hypertension (\> 150/100 mmHg); * serious trauma (e.g. MVA) within the previous 12 months; * diagnosed bleeding/clotting disorders; those currently under chiropractic care or having contraindications to Activator care (e.g. vertebral fracture, infection, active inflammatory arthritis, severe osteoporosis). The presence of these exclusions will be determined during the history and exam procedures. All female subjects will be asked to take precautions during their participation in the study to avoid becoming pregnant.

Design outcomes

Primary

MeasureTime frame
Lowered A1C Levels6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026